Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC to discuss ipecac

This article was originally published in The Tan Sheet

Executive Summary

FDA advisory committee will consider the "safety and efficacy of ipecac syrup indicated for emergency use to cause vomiting in poisoning cases for continued OTC status" during a June 12 meeting. Primary areas of consideration will be: status of the role of ipecac syrup in gastrointestinal decontamination; whether the literature clearly defines the syrup's risk/benefit ratio; the role of ipecac in poison treatment for populations with limited access to emergency medical treatment; whether there is significant abuse of ipecac; and alternative therapies to ipecac syrup, FDA says. NDAC meeting will begin at 8 a.m. at the Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS095344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel